Bright Minds Bioscience: A Deep Dive
Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright Minds Biosciences (NASDAQ: DRUG). The firm is focused on the development of second generation psychedelic pharmaceuticals for treatment of neuropsychiatric disorders, which will maintain IP protections, unlike its peers whom are largely focused on first generation psychedelic compounds.
As of the last quarter, the company had $22M cash on the balance sheet with only 12M shares outstanding. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs, with members of its scientific team including renowned scientists like Dr. Alan Kozikowski and Dr. Gideon Shapiro.
FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
